SEC Comment Letter 0000000000-22-012807 to Ascend Wellness Holdings, Inc. (AAWH)

Ascend Wellness Holdings, Inc.
Date: Nov. 28, 2022 · CIK: 0001756390 · Accession: 0000000000-22-012807

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-268534

Date

November 28, 2022

Author

Daniel Neville

Form

UPLOAD

Company

Ascend Wellness Holdings, Inc.

Letter

United States securities and exchange commission logo November 28, 2022 Daniel Neville Interim Co-Chief Executive Officer and Chief Financial Officer Ascend Wellness Holdings, Inc. 1411 Broadway, 16th Floor New York, NY 10018 Re:Ascend Wellness Holdings, Inc. Registration Statement on Form S-3 Filed November 22, 2022 File No. 333-268534 Dear Daniel Neville: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: James Guttman, Esq.

Show Raw Text

United States securities and exchange commission logo
November 28, 2022
Daniel Neville
Interim Co-Chief Executive Officer and Chief Financial Officer
Ascend Wellness Holdings, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
Re:Ascend Wellness Holdings, Inc.
Registration Statement on Form S-3
Filed November 22, 2022
File No. 333-268534
Dear Daniel Neville:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       James Guttman, Esq.

SecProbe.io